A New Chapter in StrokeDx’s Growth
We are thrilled to announce that Bob Colloton has joined StrokeDx as our new Chief Executive Officer! Bob is a seasoned leader in the stroke and neurovascular space, with a proven track record of scaling MedTech companies, securing regulatory approvals, and driving successful commercial launches.
For the past several years, StrokeDx has been on a mission to revolutionize stroke care with cutting-edge portable devices. Under the leadership of Alexander Ballatori, we’ve grown from an early-stage idea to a multi-venture-backed MedTech company, winning the MedTech Innovator Global Competition in 2023 and securing $7.7M in funding to accelerate our vision.
As we move into this next phase of clinical and commercial expansion, there is no better person to lead the charge than Bob.
Meet Bob Colloton: A Leader in Neurovascular Innovation
Bob brings decades of MedTech leadership experience, particularly in stroke and neurovascular technologies. His extensive background includes:
- CEO of MIVI Neuroscience – Led the company from early-stage development to U.S. and EU commercialization, raising $50M+ and securing multiple regulatory clearances.
- VP of Sales & Marketing at Neuravi (acquired by Johnson & Johnson) – Played a key role in launching the EmboTrap Clot Removal Device, which led to the company’s acquisition.
- Global VP at Micrus Endovascular (acquired by Johnson & Johnson) – Built and scaled the company’s sales and commercialization strategy, leading to an IPO and acquisition.
- Leadership at VNUS Medical (acquired by Medtronic) – Created global commercialization strategies for disruptive MedTech products.
Bob’s expertise in stroke care, commercialization, regulatory strategy, and team building will be pivotal as StrokeDx moves toward bringing our innovative devices to hospitals, EMS, and military settings.
A Personal Transition for Alex Ballatori
With Bob stepping in as CEO, Alexander Ballatori is transitioning out of his role to return to the Keck School of Medicine of USC and complete his medical degree. Alex founded StrokeDx with a vision to make stroke care faster and more accessible, and under his leadership, the company has grown into a major player in the stroke technology space.
While Alex is stepping away from day-to-day operations, he remains a key team member and will continue to support StrokeDx as we scale. His passion for both medicine and innovation will undoubtedly shape the future of healthcare, and we thank him for his leadership.
What’s Next for StrokeDx?
With Bob at the helm, StrokeDx is positioned to expand clinical partnerships, refine our technology, and prepare for full-scale commercialization. We are entering an exciting phase of growth, and we look forward to continuing our mission to improve stroke care and save lives.
Please join us in welcoming Bob Colloton to StrokeDx!
Stay tuned for more updates as we take StrokeDx to the next level.
Comments